Clinical impact of amyloid PET using
18F-florbetapir
Alzheimer’s disease
Amyloid
PET
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
29
08
2022
accepted:
27
09
2022
pubmed:
5
10
2022
medline:
19
11
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
Amyloid positron emission tomography (PET) can reliably detect senile plaques and fluorinated ligands are approved for clinical use. However, the clinical impact of amyloid PET imaging is still under investigation. The aim of this study was to evaluate the diagnostic impact and clinical utility in patient management of amyloid PET using Ninety-nine patients suspected of having AD underwent Visual interpretation obtained 48 positive and 51 negative PET scans. The amyloid PET results changed the AD and non-AD diagnosis in 39 of 99 patients (39.3%). The change rates of 26 of the 54 patients (48.1%) with a pre-scan AD diagnosis were significantly higher than those of 13 of the 45 patients with a pre-scan non-AD diagnosis (χ Amyloid PET using
Identifiants
pubmed: 36194355
doi: 10.1007/s12149-022-01792-y
pii: 10.1007/s12149-022-01792-y
pmc: PMC9668773
doi:
Substances chimiques
florbetapir
6867Q6IKOD
Ethylene Glycols
0
Aniline Compounds
0
Amyloid
0
Amyloid beta-Peptides
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039-1049Informations de copyright
© 2022. The Author(s).
Références
JAMA. 2019 Apr 2;321(13):1286-1294
pubmed: 30938796
J Nucl Med. 2012 Mar;53(3):378-84
pubmed: 22331215
Alzheimers Res Ther. 2021 May 10;13(1):99
pubmed: 33971965
J Nucl Med. 2010 Jun;51(6):913-20
pubmed: 20501908
Alzheimers Dement. 2019 Feb;15(2):205-216
pubmed: 30347188
Alzheimers Dement. 2018 Dec;14(12):1565-1571
pubmed: 30006100
Alzheimers Res Ther. 2020 Mar 4;12(1):22
pubmed: 32131891
Mol Neurodegener. 2014 Feb 03;9:10
pubmed: 24484858
Dement Geriatr Cogn Disord. 2016;41(1-2):80-92
pubmed: 26745445
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621-31
pubmed: 22252372
J Alzheimers Dis. 2016 Oct 18;54(4):1297-1302
pubmed: 27567830
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Eur J Nucl Med Mol Imaging. 2017 May;44(5):850-857
pubmed: 27966045
Lancet Neurol. 2012 Aug;11(8):669-78
pubmed: 22749065
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
pubmed: 25443857
Alzheimers Dement. 2018 Mar;14(3):293-305
pubmed: 29107051
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Neurology. 2017 Dec 12;89(24):2438-2446
pubmed: 29150540
Alzheimers Res Ther. 2017 Jan 17;9(1):2
pubmed: 28093088
Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):610-21
pubmed: 23341826
Brain Behav. 2022 Mar;12(3):e2499
pubmed: 35134278
J Neuropathol Exp Neurol. 2011 Nov;70(11):960-9
pubmed: 22002422
AJNR Am J Neuroradiol. 2015 Jul;36(7):1237-44
pubmed: 25767185
J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):294-299
pubmed: 29018162
Dement Geriatr Cogn Disord. 2017;44(3-4):129-143
pubmed: 28787712
EJNMMI Phys. 2016 Dec;3(1):23
pubmed: 27709546
Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):4-15
pubmed: 23203162
JAMA. 2015 May 19;313(19):1939-49
pubmed: 25988463
JAMA Neurol. 2016 Dec 01;73(12):1417-1424
pubmed: 27802513
J Nucl Med. 2017 Nov;58(11):1711-1717
pubmed: 28818990
J Alzheimers Dis. 2016 Apr 18;52(4):1251-62
pubmed: 27104896